Search

Displaying results 2751 - 2760 of 10000 in total
  1. Drug

    L-Acetylleucine

    go.drugbank.com/drugs/DB16956
    ApprovedInvestigational

    DL-) form has been available in France since 1957 for the treatment of vertigo. … [A264439] In September 2024, the FDA approved levacetylleucine for the treatment of select patients with NPC.[L51444]

    Synonyms: N-acetyl leucine, N-acetylleucine
  2. Drug

    Influenza A virus A/Hong Kong/2671/2019 NIB-121 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15710
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: Fluarix Quadrivalent 2020/2021, Fluarix Tetra Injektionssuspension in einer Fertigspritze
  3. Drug

    Cholecystokinin

    go.drugbank.com/drugs/DB08862
    ApprovedInvestigationalWithdrawn

    Recent studies have suggested that cholecystokinin also plays a major role in inducing drug tolerance to opioids such as morphine and heroin, and is partially implicated in experiences of pain hypersensitivity … Normally, it is an endogenous hormone but is available commercially for diagnostic processes and replacement in pancreatic insufficiency [L1646, L1647, L1648]. in the octapeptide form.

  4. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    brexanolone may also be undergoing clinical trials to investigate its abilities to treat super-refractory status epilepticus, it appears that some such studies have failed to meet primary endpoints that compare … In particular, the use of brexanolone in treating PPD is surrounded with promise because it acts in part as a synthetic supplement for possible deficiencies in endogenous brexanolone (allopregnanolone)

    Synonyms: allopregnan-3α-ol-20-one
  5. Drug

    Tepotinib

    go.drugbank.com/drugs/DB15133
    ApprovedInvestigational

    Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February … Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma,[A228053] gastric cancers,[A228033] non-small cell lung cancer, and hepatocellular carcinoma.

  6. Drug

    Suzetrigine

    go.drugbank.com/drugs/DB18927
    ApprovedInvestigational

    [A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098] … Suzetrigine is a Na<sub>V</sub>1.8 voltage-gated sodium channel blocker with analgesic properties[A264948] Na<sub>V</sub>1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain

  7. Drug

    Levomefolic acid

    go.drugbank.com/drugs/DB11256
    Approved

    Levomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma … It is transported across the membranes including the blood-brain barrier into various tissues where it plays an essential role in the DNA synthesis, cysteine cycle and regulation of homocysteine, where

    Synonyms: N-[4-[[[(6S)-2-Amino-3,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl]methyl]amino]benzoyl]-L-glutamic acidMixtures: PNV Tabs 20-1, Enl
  8. Target

    ATP synthase F(1) complex subunit delta, mitochondrial

    go.drugbank.com/bio_entities/BE0000484
    TargetEnzymeHumans

    ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). … Subunit delta, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated

    Polypeptides: ATP synthase F(1) complex subunit delta, mitochondrial
  9. Target

    Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex

    go.drugbank.com/bio_entities/BE0001298
    TargetAzotobacter vinelandii

    The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2).

    Polypeptides: Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complexSynonyms: Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex
  10. Target

    ATP synthase F(1) complex subunit alpha, mitochondrial

    go.drugbank.com/bio_entities/BE0003840
    TargetHumans

    ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). … Subunit alpha, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated

    Polypeptides: ATP synthase F(1) complex subunit alpha, mitochondrial